Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | AHCY | P23526 | 6/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718524 | 1.00 | POLB (0.45) | POLBENPP1P2RY1ADORA1AHCY | |
| SCHEMBL715688 | 0.86 | P2RX3 (0.39) | POLBADORA1AHCYP2RX3P2RX4 | |
| SCHEMBL5348155 | 0.83 | CHKA (0.42) | POLBENPP1P2RY1ADORA1AHCY | |
| SCHEMBL719007 | 0.78 | POLB (0.43) | POLB | |
| SCHEMBL888069 | 0.78 | POLB (0.46) | POLBENPP1P2RY1AHCYSTING1 | |
| SCHEMBL888256 | 0.77 | STING1 (0.42) | POLBENPP1P2RY1AHCYSTING1 | |
| SCHEMBL1901202 | 0.77 | POLB (0.42) | POLBENPP1P2RY1ADORA1AHCY | |
| SCHEMBL5859661 | 0.77 | P2RX3 (0.43) | POLBENPP1P2RY1ADORA1AHCY | |
| SCHEMBL2952877 | 0.76 | POLB (0.44) | POLBENPP1P2RY1ADORA1AHCY | |
| SCHEMBL3969539 | 0.76 | AHCY (0.49) | POLBENPP1P2RY1ADORA1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN SCIENCES, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20210230686-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | IsoPlexis Corporation | 2021-07-29 | — | — | US | disclosed |
| US-20210231609-A1 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | IsoPlexis Corporation | 2021-07-29 | — | — | US | disclosed |
| US-11035823-B2 | Methods and devices for sequencing nucleic acids in smaller batches | QIAGEN SCIENCES, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-11001887-B2 | Methods and compositions for incorporating nucleotides | QIAGEN SCIENCES, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10745740-B2 | Sample preparation | QIAGEN SCIENCES, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200149089-A9 | Sample Preparation | IsoPlexis Corporation | 2020-05-14 | — | — | US | disclosed |
| US-20200040391-A1 | Methods and Compositions for Incorporating Nucleotides | IsoPlexis Corporation | 2020-02-06 | — | — | US | disclosed |
| US-8623598-B2 | Methods and compositions for inhibiting undesired cleaving of labels | Intelligent Bio Systems, Inc. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8612161-B2 | Methods and compositions for base calling nucleic acids | INTELLIGENT BIOSYSTEMS INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130316914-A1 | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches | INTELLIGENT BIOSYSTEMS, INC. | 2013-11-28 | — | — | US | disclosed |
| US-20130301888-A1 | Methods And Compositions For Base Calling Nucleic Acids | IsoPlexis Corporation | 2013-11-14 | — | — | US | disclosed |
| US-8481259-B2 | Methods and devices for sequencing nucleic acids in smaller batches | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130137091-A1 | Methods And Compositions For Incorporating Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20100323350-A1 | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches | INTELLIGENT BIOSYSTEMS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100063743-A1 | Methods And Compositions For Base Calling Nucleic Acids | INTELLIGENT BIO-SYSTEMS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100035253-A1 | Methods And Compositions For Incorporating Nucleotides | INTELLIGENT BIO-SYSTEMS, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2009117119-A1 | METHODS AND COMPOSITIONS FOR BASE CALLING NUCLEIC ACIDS | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230686-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885ENPP1 165/4885P2RY1 217/4885 |
| US-20200040391-A1 | Methods and Compositions for Incorporating Nucleotides | NT5C2, NOP2, NT5C3B | POLB 44/4885ENPP1 165/4885P2RY1 217/4885 |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885ENPP1 165/4885P2RY1 217/4885 |
| US-11001887-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | POLB 44/4885ENPP1 165/4885P2RY1 217/4885 |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885ENPP1 165/4885P2RY1 217/4885 |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | POLB 44/4885ENPP1 165/4885P2RY1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.